IP Library Patent Application 16911716
Patent Application
App. No. 16/911,716

PROCESS FOR PRODUCING AN EXTRACT CONTAINING TETRAHYDROCANNABINOL AND CANNABIDIOL FROM CANNABIS PLANT MATERIAL, AND CANNABIS EXTRACTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/911,716
Abstract

The invention relates to a method for producing an extract from cannabis plant matter, containing tetrahydrocannabinol, cannabidiol and optionally the carboxylic acids thereof. According to said method, the dried plant matter is ground and subjected to a CO 2 extraction and the primary extract obtained is separated. The invention method permits Δ 8 or Δ 9 tetrahydrocannabinol to be selectively obtained both from industrial hemp and from drug-producing hemp, optionally after dissolving the primary extract in ethanol, separating undesirable waxes and removing the solvent under reduced pressure.

Claims (29)

1 . A process for producing an extract containing tetrahydrocannabinol, cannabidiol and optionally the carboxylic acids thereof from Cannabis plant material, wherein the dried plant material is comminuted;

characterized in that

said plant material is extracted by means of CO 2 under supercritical pressure and temperature conditions at a temperature in a range of approx. 31° C. to 80° C. and at a pressure in a range of approx. 75 bar or 500 bar, or

is extracted in the subcricital range at a temperature of approx. 20° C. to 30° C. and a supercritical pressure of approx. 100 bar to 350 bar; or

is extracted under subcricital pressure and temperature conditions; and

the obtained primary extract is separated out under subcricital conditions or under conditions subcricital in terms of pressure and supercritical in terms of temperature.

2 . The process according to claim 1 , characterized in that plant material of Cannabis sativa L., in particular hemp of the fiber type and/or hemp of the drug type, is employed as cannabis plant material.

3 . The process according to claim 1 , characterized in that to the CO 2 an entraining agent is added which is selected from the group comprised of: propane, butane, ethanol, and water.

4 . The process according to claim 1 , characterized in that in the supercritical range a temperature of approx. 45° C. to approx. 65° C. and a pressure of approx. 100 bar to 350 bar, preferably a temperature of approx. 60° C. and a pressure of approx. 250 bar, are used.

5 . The process according to claim 1 , characterized in that an adsorbent is arranged on the material to be extracted downstream in terms of the CO 2 flow.

6 . The process according to claim 5 , characterized in that the adsorbent is selected from the group comprised of: silica gel, diatomaceous earth, bentonites, bleaching earth, activated carbons, in particular magnesium oxide and alumina, as well as mixtures thereof.

7 . The process according to claim 1 , characterized in that extraction is repeated at least once, with extraction preferably being repeated with diatomaceous earth and/or another adsorbent.

8 . A primary extract from cannabis plant material, containing tetrahydrocannabinol and cannabidiol and optionally the carboxylic acids thereof,

characterized in that

it may be obtained through a process in accordance with claim 1 ; and

in that it contains at least reduced proportions of monoterpene and sesquiterpene hydrocarbons, alkaloids, flavonoids and chlorophylls.

9 . A primary extract according to claim 8 , characterized in that tetrahydrocannabinol includes at least Δ 9 -tetrahydrocannabinol and/or Δ 8 -tetrahydrocannabinol and/or the carboxylic acids thereof.

10 . A primary extract according to claim 8 , characterized in that tetrahydrocannabinol and/or the carboxylic acids thereof are the main constituent if a hemp of the drug type is used as a starting material.

11 . A primary extract according to claim 8 , characterized in that cannabidiol and/or the carboxylic acids thereof are the main constituent if a hemp of the fiber type is used as a starting material.

12 . A primary extract according to claim 8 , characterized in that it is dissolved in ethanol, separated from waxes not soluble therein, and the solvent is again removed under reduced pressure.

13 . A process for producing tetrahydrocannabinol from the primary extract in accordance with claim 8 ,

characterized in that

in the primary extract cannabidiolic acid and tetrahydrocannabidiolic acid are decarboxylated into cannabidiol and tetrahydrocannabinol through increase in temperature;

the decarboxylated primary extract is dissolved in the CO 2 extracting agent used, and in this condition is treated by means of a high-pressure vessel charged with a catalyst for anellation of cannabidiol into tetrahydrocannabinol and a water-binding agent, wherein cannabidiol is reacted to give tetrahydrocannabinol; and

the product enriched in tetrahydrocannabinol is separated at pressure and temperature conditions subcricital for CO 2 .

14 . A process for producing cannabidiol from the primary extract in accordance with claim 8 ,

characterized in that

in the primary extract cannabidiolic acid and tetrahydrocannabidiolic acid are decarboxylated into cannabidiol and tetrahydrocannabinol through increase in temperature; and

subsequently the cannabidiol is separated through column chromatography on silica gel or preparative high-pressure liquid chromatography.

Assignments (5)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 22, 2021
From: CANOPY GROWTH CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055683/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2020
From: SPECTRUM THERAPEUTICS GMBH
To: CANOPY GROWTH CORPORATION
Reel/Frame 054547/0815 →
CHANGE OF NAME Recorded Dec 4, 2020
From: BIONORICA ETHICS GMBH
To: SPECTRUM THERAPEUTICS GMBH
Reel/Frame 054600/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2020
From: MUELLER, ADAM
To: DELTA-9-PHARMA GMBH
Reel/Frame 053253/0377 →
CHANGE OF NAME Recorded Jul 20, 2020
From: DELTA-9-PHARMA GMBH
To: BIONORICA ETHICS GMBH
Reel/Frame 053254/0490 →